Log in

NASDAQ:RMTIRockwell Medical Stock Price, Forecast & News

$2.09
+0.29 (+16.11 %)
(As of 04/7/2020 03:08 AM ET)
Add
Compare
Today's Range
$1.82
Now: $2.09
$2.14
50-Day Range
$1.56
MA: $2.58
$3.57
52-Week Range
$1.31
Now: $2.09
$5.80
Volume1.07 million shs
Average Volume1.42 million shs
Market Capitalization$144.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. It is also developing an intravenous formulation of Triferic for use by hemodialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1994 and is based in Wixom, Michigan.
Read More
Rockwell Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:RMTI
CUSIP77437410
Phone248-960-9009

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$61.30 million
Book Value$0.32 per share

Profitability

Net Income$-34,130,000.00

Miscellaneous

Employees269
Market Cap$144.31 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive RMTI News and Ratings via Email

Sign-up to receive the latest news and ratings for RMTI and its competitors with MarketBeat's FREE daily newsletter.


Rockwell Medical (NASDAQ:RMTI) Frequently Asked Questions

How has Rockwell Medical's stock been impacted by COVID-19 (Coronavirus)?

Rockwell Medical's stock was trading at $2.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RMTI shares have decreased by 27.4% and is now trading at $2.09. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rockwell Medical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rockwell Medical.

When is Rockwell Medical's next earnings date?

Rockwell Medical is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Rockwell Medical.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical Inc (NASDAQ:RMTI) issued its earnings results on Thursday, March, 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.01. The firm earned $15.49 million during the quarter, compared to analyst estimates of $16.56 million. Rockwell Medical had a negative return on equity of 145.57% and a negative net margin of 55.67%. View Rockwell Medical's earnings history.

What price target have analysts set for RMTI?

4 brokerages have issued 1 year price objectives for Rockwell Medical's shares. Their forecasts range from $6.00 to $11.00. On average, they expect Rockwell Medical's share price to reach $9.33 in the next year. This suggests a possible upside of 346.6% from the stock's current price. View analysts' price targets for Rockwell Medical.

Has Rockwell Medical been receiving favorable news coverage?

Media coverage about RMTI stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Rockwell Medical earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutRockwell Medical.

Are investors shorting Rockwell Medical?

Rockwell Medical saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 6,810,000 shares, an increase of 17.8% from the February 13th total of 5,780,000 shares. Based on an average daily volume of 991,100 shares, the days-to-cover ratio is currently 6.9 days. Currently, 12.1% of the company's shares are short sold. View Rockwell Medical's Current Options Chain.

Who are some of Rockwell Medical's key competitors?

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seattle Genetics (SGEN), Agile Therapeutics (AGRX), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Eyepoint Pharmaceuticals (EYPT), ImmunoGen (IMGN), Novavax (NVAX) and VBI Vaccines (VBIV).

Who are Rockwell Medical's key executives?

Rockwell Medical's management team includes the following people:
  • Mr. Stuart Paul, Pres, CEO & Director (Age 59)
  • Mr. Angus W. Smith, Chief Financial Officer (Age 36)
  • Dr. Ajay Gupta, Chief Scientific Officer & Member of Scientific Advisory Board (Age 61)
  • Mr. Michael DeYoung, VP of Operations
  • Mr. David J. Kull, Principal Accounting Officer, Sec. & Controller (Age 51)

What is Rockwell Medical's stock symbol?

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

How do I buy shares of Rockwell Medical?

Shares of RMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rockwell Medical's stock price today?

One share of RMTI stock can currently be purchased for approximately $2.09.

How big of a company is Rockwell Medical?

Rockwell Medical has a market capitalization of $144.31 million and generates $61.30 million in revenue each year. The company earns $-34,130,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Rockwell Medical employs 269 workers across the globe. View additional information about Rockwell Medical.

What is Rockwell Medical's official website?

The official website for Rockwell Medical is http://www.rockwellmed.com/.

How can I contact Rockwell Medical?

Rockwell Medical's mailing address is 411 HACKENSACK AVE. SUITE 501, HACKENSACK NJ, 07601. The company can be reached via phone at 248-960-9009 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel